secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nemaura Medical Inc. (—)
CIK:        0001602078
Form:       8-K
Filed at:   2023-11-21T23:59:59+00:00
Accession:  0001079973-23-001636
Event type: debt
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.03, 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nemaura Medical secures $10M credit facility with Streeterville Capital, non-dilutive funding for growth
--------------------------------------------------------------------------------

- Line of credit facility for up to $10M from Streeterville Capital; maximum draw of $1M per month.
- Monitoring fee of 0.8333% per month on outstanding draws; 20% original issue discount added per draw.
- Facility secured by all assets of Nemaura, Dermal Diagnostics, and Trial Clinic.
- Management states structure minimizes dilution compared to equity sales, supporting commercialization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1602078/000107997323001636/0001079973-23-001636-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1602078/000107997323001636/nmra_8k.htm
  HTML page:      https://secwatch.observer/filing/0001079973-23-001636

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer